Cabozantinib (new indication: thyroid carcinoma, pretreated patients, refractory to radioactive iodine)

Subject:

• Active Substance: Cabozantinib
• Name: Cabometyx^®
• Therapeutic area: Thyroid carcinoma
• Pharmaceutical company: Ipsen Pharma GmbH

Time table:

• Start: 01.06.2022
• Final decision by G-BA: 01.12.2022

Final decision:

• No additional benefit proved